Minister unlikely to delay Russian clinical trial revisions, says anti-monopolies chief
This article was originally published in Scrip
After two years of investigation into both corruption and maladministration at the Russian Ministry of Health, the Federal Antimonopoly Service is asking the Ministry of Health and the Russian Parliament to make a long list of key amendments both to the legislation and to practice at the ministry.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.